ATS 2024 Final Program

Click on the session title to view the speakers

239

TUESDAY • MAY 21

P594 Mortality Among US Adults With Severe Asthma Is Increased With Maintenance Systemic Corticosteroid Treatment: Results From the CHRONICLE Study P595 Clinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study P596 Impact of Early Transient Increase in Eosinophil Count on the Long-term Efficacy of Dupilumab in Patients With Moderate-to-Severe Asthma: Liberty Asthma Traverse P597 Clinically Relevant Reductions in FeNO Reported After 10-day Treatment With KN-002 in Subjects With Mild Asthma P598 Requirement of TRPA1 in Oxidized Phosphatidylcholine Induced Pro-inflammatory Gene Expression by Human Airway Fibroblasts P599 Opioid Use Disorder’s Influence on Asthma Exacerbation Outcomes: Insights From the National Inpatient Sample P600 Predictive Roles of Basal Metabolic Rate and Muscle Mass for Lung Function in Obese Asthma: A Prospective Cohort Study P601 Ultra-high-resolution Computed Tomography Assessment of Airway Structure in Bronchial Asthma: Associations With Fractional Exhaled Nitric Oxide P602 Characteristics of T2-low and T2-high Asthma in a Population-based Sample Defined by Blood Eosinophils and Fractional Exhaled Nitric Oxide P603 Navigating Non-T2 Asthma: Impact of Bacterial Colonization and Inflammatory Subtype on Asthma Exacerbations P604 Efficacy of As-needed Albuterol-budesonide by Baseline Blood Eosinophil Count in Patients ³ 18years With Moderate-to-Severe Asthma P605 Comparison of Exhaled Volatile Organic Compounds Among Severe Asthma Phenotypes in Japan: A J-VOCSA Study P606 Construction of an Automated Algorithm for Diagnosis of Adult Asthma Using Machine Learning With Category Boosting (CatBoost)

P607 Predicting Asthma Exacerbations: A Real World Study Examining the Biologic and Demographic Makeup of Patients With Severe Asthma P608 Development of the Pediatric Asthma Impairment and Risk Questionnaire (AIRQ ® ): A Qualitative Study P609 The Differential Effects of Inhaled and Oral Corticosteroids on Type-2 Inflammation in the Blood and Airway Compartments of Eosinophilic Asthmatics P610 Asthma Prevalence Differs by Primary Spoken Language Among US Chinese and Latino Adults P611 Influence of Different Thresholds for Asthma Control on Clinical Remission Composite Outcome in Patients Uncontrolled on ICS/LABA: A Post-hoc Analysis of Single Inhaler Triple Therapy With FF/UMEC/VI in the CAPTAIN Trial P612 Improved Lung Function Is Associated With Better Asthma Control in Adolescents and Adults Aged 12 Years and Older With Moderate-To-Severe Type 2 Asthma: A Post Hoc Analysis of Quest P613 Repeated Measurement of Spirometry and Type 2 Biomarkers to Diagnose and Identify Refractory Asthma in a Population of Symptomatic Individuals With Clinically Suspected Asthma P614 Biologics for Severe Asthma in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap P615 Three-year Follow-up in the Selection of Inhalation Therapies for Severe Asthma in Japan P616 A Bayesian Dynamic Borrowing Approach to Evaluate the Efficacy of Albuterol-budesonide as Needed in Adolescents With Asthma: Design of the Acadia Study P617 Role of Dietary and Serum Selenium Across Asthma Phenotypes P618 Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis P619 Phenotyping of Asthma Patients Based on Inflammatory Blood Biomarkers and Characterization of Phenotypes Depending on Asthma Control, Frequency of Exacerbations, and Associated Comorbidities

ATS 2024 Conference Program • San Diego, CA